Back to first-pass browser

First-pass extracted concept

feladilimab

Candidate: toolkit item1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

GSK3359609

Extracted Explainers

What the tool is doing

Feladilimab is presented as an ICOS agonist used in the phase I INDUCE-1 study for advanced solid tumors. The abstract states that it achieved robust receptor occupancy with favorable safety.

Source 1DOIPubMed

What problem it solves

It is intended to therapeutically engage the ICOS co-stimulatory pathway in cancer. The paper frames this as a way to harness immune agonism in solid tumors.

Source 1DOIPubMed

What it does not solve

The abstract states that receptor engagement alone was not sufficient for strong clinical responses. Limited clinical responses indicate that feladilimab does not by itself overcome the broader context dependence of ICOS modulation.

Source 1DOIPubMed

Alternatives

The abstract explicitly contrasts feladilimab with vopratelimab and refers more broadly to future agonistic or antagonistic, monoclonal or bispecific ICOS-directed strategies.

Source 1DOIPubMed

Evidence Snippets

The phase I INDUCE-1 study of the ICOS agonist feladilimab (GSK3359609) employed a pharmacodynamically guided design that prioritized biological activity over toxicity thresholds.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1clinical observationmixed2026Source 1DOIPubMed

Feladilimab showed favorable safety and robust receptor occupancy but limited clinical responses.

Quoted textsource-backed
Although feladilimab demonstrated favorable safety and robust receptor occupancy, clinical responses were limited
Claim 2comparative clinical observationsupports2026Source 1DOIPubMed

Limited clinical responses with feladilimab echo similar experiences with vopratelimab and other ICOS agonists.

Quoted textsource-backed
clinical responses were limited-echoing similar experiences with vopratelimab (JTX-2011) and other ICOS agonists.
Claim 3workflow designsupports2026Source 1DOIPubMed

INDUCE-1 used a pharmacodynamically guided design that prioritized biological activity over toxicity thresholds.

Quoted textsource-backed
The phase I INDUCE-1 study of the ICOS agonist feladilimab (GSK3359609) employed a pharmacodynamically guided design that prioritized biological activity over toxicity thresholds.